The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.
Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.
Men with metastatic castration-resistant prostate cancer who had mutations in genes like BRCA1 and BRCA2 benefited from treatment with olaparib.
Two studies showed that the addition of abemaciclib or ribociclib to fulvestrant improved overall survival in HR-positive, HER2-negative breast cancer patients.
Two KEYNOTE studies showed TMB may have some utility in determining which NSCLC patients should get pembrolizumab, while three others showed no utility.
The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.
Results from the CheckMate-227 trial provided evidence for the use of nivolumab and ipilimumab in combination, while the FLAURA study focused on osimertinib.
An interim analysis of the IMpower110 study showed that the drug performed better as a first-line treatment than chemotherapy in these patients.
Whether they're analyzing checkpoint inhibitors, CAR T cells, or combination regimens, pediatric cancer researchers must carefully consider which targets and drugs to trial.